Rothschild Investment LLC’s Summit Therapeutics SMMT Stock Holding History

Rothschild Investment LLC’s Portfolio SMMT Stock Details SMMT Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$204	Buy	14 +11	+367%	+$195	﹤0.01%	3434
2026 Q1	$57	Buy	3 +1	+50%	+$16	﹤0.01%	3450
2025 Q4	$35	Buy	2 +1	+100%	+$19	﹤0.01%	3300
2025 Q3	$21	Buy	+1	New	+$24	﹤0.01%	3118
2025 Q2	–	Sell	-195	Closed	-$3.76K	–	3174
2025 Q1	$3.76K	Buy	195 +75	+63%	+$1.5K	﹤0.01%	1571
2024 Q4	$2.14K	Sell	120 -10	-8%	-$194	﹤0.01%	1759
2024 Q3	$2.85K	Buy	130 +75	+136%	+$1.05K	﹤0.01%	1545
2024 Q2	$429	Buy	+55	New	+$297	﹤0.01%	2114

Other funds holding SMMT

BBA

Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

Point72 Asset Management Stamford, Connecticut $90.7B AUM 77.13% 1-Year Est. Return

Rothschild Investment LLC's SMMT Position: Q2 2026 in Review

Rothschild Investment LLC increased its Summit Therapeutics (SMMT) stake by 367% in Q2 2026, buying an estimated $195 and bringing the position to 14 shares worth $204. The position accounts for ﹤0.01% of the portfolio, ranked #3434.

Rothschild Investment LLC first reported a position in SMMT in Q2 2024 and has held it in 8 quarters since. The position peaked at $3.76K in Q1 2025. 242 funds tracked by Wall St. Rank hold SMMT as of Q2 2026.

Rothschild Investment LLC held 14 shares of Summit Therapeutics worth $204 as of Q2 2026.
Rothschild Investment LLC bought 11 Summit Therapeutics shares in Q2 2026, an estimated $195.
Summit Therapeutics made up ﹤0.01% of Rothschild Investment LLC's portfolio in Q2 2026, its #3434 holding.
Rothschild Investment LLC first reported a position in Summit Therapeutics in Q2 2024 and has held it in 8 quarters since.
Rothschild Investment LLC's Summit Therapeutics position peaked at $3.76K in Q1 2025.
242 funds tracked by Wall St. Rank held Summit Therapeutics as of Q2 2026.

Based on Rothschild Investment LLC's 13F filing for Q2 2026, filed 6 Aug 2026.